PortfoliosLab logoPortfoliosLab logo
CAI vs. TLX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CAI vs. TLX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Caris Life Sciences, Inc (CAI) and Telix Pharmaceuticals Ltd (TLX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CAI achieves a -42.62% return, which is significantly lower than TLX's 17.09% return.


CAI

1D
-6.30%
1M
-17.17%
YTD
-42.62%
6M
-43.17%
1Y
3Y*
5Y*
10Y*

TLX

1D
-4.26%
1M
-21.35%
YTD
17.09%
6M
-9.21%
1Y
-48.32%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

CAI vs. TLX - Yearly Performance Comparison


2026 (YTD)2025
CAI
Caris Life Sciences, Inc
-42.62%-3.64%
TLX
Telix Pharmaceuticals Ltd
17.09%-55.84%

Correlation

The correlation between CAI and TLX is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (All Time)
Calculated using the full available price history since Jun 20, 2025

0.09

Fundamentals

Market Cap

CAI:

$4.37B

TLX:

$2.97B

EPS

CAI:

$0.05

TLX:

$0.12

PE Ratio

CAI:

287.88

TLX:

75.65

PEG Ratio

CAI:

1.10

TLX:

0.09

PS Ratio

CAI:

10.78

TLX:

1.48

PB Ratio

CAI:

7.37

TLX:

4.77

Total Revenue (TTM)

CAI:

$907.29M

TLX:

$2.00B

Gross Profit (TTM)

CAI:

$482.11M

TLX:

$1.13B

EBITDA (TTM)

CAI:

$92.24M

TLX:

$153.71M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Caris Life Sciences, Inc

Telix Pharmaceuticals Ltd

Often compared with TLX:
TLX vs. MSTR

Return for Risk

CAI vs. TLX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CAI

TLX
TLX Risk / Return Rank: 1212
Overall Rank
TLX Sharpe Ratio Rank: 88
Sharpe Ratio Rank
TLX Sortino Ratio Rank: 99
Sortino Ratio Rank
TLX Omega Ratio Rank: 1111
Omega Ratio Rank
TLX Calmar Ratio Rank: 1313
Calmar Ratio Rank
TLX Martin Ratio Rank: 1717
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CAI vs. TLX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Caris Life Sciences, Inc (CAI) and Telix Pharmaceuticals Ltd (TLX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

CAI vs. TLX - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


CAITLXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.83

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.75

-0.53

-0.22

Drawdowns

CAI vs. TLX - Drawdown Comparison

The maximum CAI drawdown since its inception was -62.98%, smaller than the maximum TLX drawdown of -69.37%. Use the drawdown chart below to compare losses from any high point for CAI and TLX.


Loading charts...

Drawdown Indicators


CAITLXDifference

Max Drawdown

Largest peak-to-trough decline

-62.98%

-69.37%

+6.39%

Max Drawdown (1Y)

Largest decline over 1 year

-63.33%

Current Drawdown

Current decline from peak

-60.61%

-58.10%

-2.51%

Average Drawdown

Average peak-to-trough decline

-31.05%

-36.51%

+5.46%

Ulcer Index

Depth and duration of drawdowns from previous peaks

43.36%

Volatility

CAI vs. TLX - Volatility Comparison


Loading charts...

Volatility by Period


CAITLXDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.21%

Volatility (6M)

Calculated over the trailing 6-month period

40.70%

Volatility (1Y)

Calculated over the trailing 1-year period

62.20%

58.24%

+3.96%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

62.20%

57.09%

+5.11%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

62.20%

57.09%

+5.11%

Dividends

CAI vs. TLX - Dividend Comparison

Neither CAI nor TLX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CAI vs. TLX - Financials Comparison

This section allows you to compare key financial metrics between Caris Life Sciences, Inc and Telix Pharmaceuticals Ltd. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00M600.00M20222023202420252026
216.17M
620.44M
(CAI) Total Revenue
(TLX) Total Revenue
Values in USD except per share items

CAI vs. TLX - Profitability Comparison

The chart below illustrates the profitability comparison between Caris Life Sciences, Inc and Telix Pharmaceuticals Ltd over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-50.0%0.0%50.0%202220232024202520260
52.8%
Portfolio components
CAI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Caris Life Sciences, Inc reported a gross profit of 0.00 and revenue of 216.17M. Therefore, the gross margin over that period was 0.0%.

TLX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Telix Pharmaceuticals Ltd reported a gross profit of 327.42M and revenue of 620.44M. Therefore, the gross margin over that period was 52.8%.

CAI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Caris Life Sciences, Inc reported an operating income of 5.28M and revenue of 216.17M, resulting in an operating margin of 2.4%.

TLX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Telix Pharmaceuticals Ltd reported an operating income of 9.82M and revenue of 620.44M, resulting in an operating margin of 1.6%.

CAI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Caris Life Sciences, Inc reported a net income of -510.00K and revenue of 216.17M, resulting in a net margin of -0.2%.

TLX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Telix Pharmaceuticals Ltd reported a net income of -7.25M and revenue of 620.44M, resulting in a net margin of -1.2%.


Frequently Asked Questions


CAI and TLX have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for CAI and TLX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer